Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis
August 5th 2023Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.
Read More
Study Finds Neurocutaneous Syndromes Increase Childhood Cancer Risk
August 5th 2023Using data from the Swedish National Medical Birth Register, researchers found that different neurocutaneous syndromes are associated with increased risk of childhood cancer, especially central nervous system tumors.
Read More
Nirmatrelvir-Ritonavir Reduces Risk of COVID-19 Hospitalization, Death, Study Finds
August 4th 2023The body of research on nirmatrelvir-ritonavir demonstrates a plethora of benefits in the treatment of COVID-19, and authors of a recent study identified more advantages to administering the treatment to patients with COVID-19.
Read More
COPD Exacerbations More Common in Unmedicated Patients, but Many Remain Untreated
August 4th 2023Most chronic obstructive pulmonary disease (COPD) exacerbations were observed in those not treated with controller medications, but less than half of patients in the study received controller medications, even after exacerbations.
Read More
What We’re Reading: Historic Low of Uninsured; Youth Gender Treatments; Birth Control Recall
August 4th 2023A record low of 7.7% of Americans had no health insurance at the start of 2023; the American Academy of Pediatrics renewed its backing of gender care for children while requesting a research review; 2 lots of an oral contraceptive were recalled for possible reduction in effectiveness.
Read More
Two-Step Testing Helps Predict and Treat Recurrent C difficile Infection
August 3rd 2023This study explores the effectiveness of toxin testing in predicting Clostridioides difficile infection (CDI) outcomes, revealing that patients with negative toxin results were less likely to experience CDI recurrence within 30 days.
Read More
Delays Between CRC Presentation, Treatment Not Associated With Poor Survival in Young Adults
August 3rd 2023Adults younger than 50 years with colorectal cancer (CRC) who experience postpresentation delays in treatment did not appear to have worse outcomes, according to a study in Ontario, Canada.
Read More